Online Event
The landscape of novel monoclonal antibody (mAb) therapeutic formats has expanded significantly in recent years, introducing new challenges in the purification process. Traditional full-length IgG molecules are now supplemented by antigen-binding fragments, bispecific antibodies, and antibody-drug conjugates, each with unique physicochemical properties and structural differences. These diverse formats require tailored purification strategies due to variations in their fundamental structure and modified